SEC Tracker
Get the app
RGNX · XBRL financial data

REGENXBIO financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers2922*16222421*89213030*6108
Cost of goods and services sold1211*411126*——————
Research and development5856*55495450*53605660*5756
General and administrative2319*18191920*20202022*2122
Operating income (loss)(65)(64)*(64)(56)(62)(51)*12(63)(52)(58)*(83)29
Interest income—year only3433*3343*21
Interest expense21*2019*9111312*98
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(62)(63)*(63)(53)(60)(51)*6(71)(62)(67)*(90)23
Earnings per share, basic USD per share(1.41)—(1.38)(1.05)(1.17)(1.01)*0.12(1.38)(1.20)(1.30)*(1.72)0.43
Earnings per share, diluted USD per share(1.41)—(1.38)(1.05)(1.17)(1.01)*0.12(1.38)(1.20)(1.30)*(1.72)0.43
Weighted average shares, basic millions of shares0—46515151*51515252*5253
Weighted average shares, diluted millions of shares0—46515151*51515252*5253

Balance sheet

CSV

Fiscal quarters (RGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents53351135857581308059341536
Marketable securities24924122623319917713824421519613569
Marketable securities, non-current6339423723105402811——
Accounts receivable2825162324201820252610107
Total current assets366335395347313278313374332281187236
Property and equipment, net13613212812412111811411110810510298
Right-of-use asset626058565554525049474644
Total assets634574629569519466491581525453342387
Accounts payable222331162023192222212116
Total current liabilities127130110981031031071201251187183
Lease liability, non-current848280787674727067656362
Total liabilities271262239221218206217367364350321315
Accumulated deficit(642)(705)(768)(821)(881)(932)(926)(997)(1,059)(1,126)(1,216)(1,193)
Total stockholders' equity3633123913483012602742141611032172
Total liabilities and equity634574629569519466491581525453342387
Common shares outstanding (cover page) millions of shares444449495050505151525266

Cash flows

CSV

Fiscal quarters (RGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(62)(63)*(63)(53)(60)(51)*6(71)(62)(67)*(90)23
Stock-based compensation10*8*109*10*10*99*9*8*99*
Net cash from operating activities(49)*(41)*(55)(45)*(41)*(32)*34(49)*(56)*(52)*(76)(62)*
Purchases of property and equipment1*1*10*0*1*10*0*1*11*
Net cash from investing activities39*34*13(0)*50*40*45(140)*42*38*7166*
Net cash from financing activities(5)*(12)*121(9)*(11)*(8)*(6)139*(7)*(10)*(14)18*
Net change in cash(16)*(19)*78(55)*(1)*1*73(51)*(21)*(24)*(19)21*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
REGENXBIO36108(62)*66.0M1.7 quarters 10-QJun 30, 2026
Cronos Group4675324*368.4M— 10-QJun 30, 2026
CytomX Therapeutics171.4(18)*217.9M18.3 quarters 10-QJun 30, 2026
Capricor Therapeutics21not reported(31)*58.1M7.6 quarters 10-QJun 30, 2026
Oruka Therapeutics268not reported(33)*66.2M26.4 quarters 10-QJun 30, 2026
Cryoport269491.1*50.6M— 10-QJun 30, 2026
CytoDyn16not reported(7.7)1.5B2.1 quarters 10-QAug 31, 2026
Emergent BioSolutions176110100*51.4M— 10-QSep 30, 2026
Northwest Biotherapeutics0.60.8(7.2)*1.7B0.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.